Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling

Angiogenesis of human peritoneal vascular endothelial cells (HPVECs), linked to vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) signaling, is a complication of peritoneal fibrosis (PF). Hippo/YAP signaling interacts with VEGF/VEGFR2 signaling, but the effect on peritoneal angiogen...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaolin Zhu (Author), Yun Shan (Author), Manshu Yu (Author), Jun Shi (Author), Lei Tang (Author), Huimin Cao (Author), Meixiao Sheng (Author)
Format: Book
Published: Frontiers Media S.A., 2021-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8c76802c520e4e5a80bfb2646ace2ee3
042 |a dc 
100 1 0 |a Xiaolin Zhu  |e author 
700 1 0 |a Xiaolin Zhu  |e author 
700 1 0 |a Yun Shan  |e author 
700 1 0 |a Manshu Yu  |e author 
700 1 0 |a Jun Shi  |e author 
700 1 0 |a Lei Tang  |e author 
700 1 0 |a Huimin Cao  |e author 
700 1 0 |a Meixiao Sheng  |e author 
245 0 0 |a Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling 
260 |b Frontiers Media S.A.,   |c 2021-04-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2021.649581 
520 |a Angiogenesis of human peritoneal vascular endothelial cells (HPVECs), linked to vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) signaling, is a complication of peritoneal fibrosis (PF). Hippo/YAP signaling interacts with VEGF/VEGFR2 signaling, but the effect on peritoneal angiogenesis and PF has not been studied. We tested VEGF/Hippo/YAP inhibition by tetramethylpyrazine (TMP) in PF mice and HPVECs. This treatment ameliorated peritoneal dialysis (PD)-induced angiogenesis and PF. In mice, PF was associated with upregulation of VEGF, and TMP ameliorated submesothelial fibrosis, perivascular bleeding, and Collagen I abundance. In HPVECs, angiogenesis occurred due to human peritoneal mesothelial cells (HPMCs)-conditioned medium, and TMP alleviated HPVECs migration, tube formation, and YAP nuclear translocation. YAP knockdown PF mouse and HPVEC models were established to further confirm our finding. YAP deletion attenuated the PD-induced or VEGF-induced increase in angiogenesis and PF. The amount of CYR61 and CTGF was significantly less in the YAP knockdown group. To study the possibility that TMP could benefit angiogenesis, we measured the HPVECs migration and tube formation and found that both were sharply increased in YAP overexpression; TMP treatment partly abolished these increases. As well, the amount of VEGFR localized in the trans-Golgi network was lower by double immunofluorescence; VEGFR and its downstream signaling pathways including p-ERK, p-P38, and p-Akt were more in HPVECs with YAP overexpression. Overall, TMP treatment ameliorated angiogenesis, PF, and peritoneum injury. These changes were accompanied by inhibition of VEGF/Hippo/YAP. 
546 |a EN 
690 |a peritoneal fibrosis 
690 |a peritoneal angiogenesis 
690 |a peritoneal vascular endothelial cells 
690 |a YAP 
690 |a Golgi 
690 |a tetramethylpyrazine 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 12 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2021.649581/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/8c76802c520e4e5a80bfb2646ace2ee3  |z Connect to this object online.